Application of bacteriophages

The emergence of antibiotic-resistant bacteria and decrease in the discovery rate of novel antibiotics takes mankind back to the ‘pre-antibiotic era’ and search for alternative treatments. Bacteriophages have been one of promising alternative agents which can be utilised for medicinal and biological control purposes in agriculture and related fields. The idea to treat bacterial infections with phages came out of the pioneering work of Felix d‘Herelle but this was overshadowed by the success of antibiotics. Recent renewed interest in phage therapy is dictated by its advantages most importantly by their specificity against the bacterial targets. This prevents complications such as antibiotic-induced dysbiosis and secondary infections. This article is compiled by the participants of the Expert Round Table conference ‘Bacteriophages as tools for therapy, prophylaxis and diagnostics’ (19–21 October 2015) at the Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi, Georgia. The first paper from the Round Table was published in the Biotechnology Journal1. This In Focus article expands from this paper and includes recent developments reported since then by the Expert Round Table participants, including the implementation of the Nagoya Protocol for the applications of bacteriophages.

[1]  S. Abedon,et al.  Bacteriophage biocontrol: the technology matures , 2008 .

[2]  K. Hopkins,et al.  Fluorescent Amplified Fragment Length Polymorphism Genotyping of Campylobacter jejuni and Campylobacter coli Strains and Its Relationship with Host Specificity, Serotyping, and Phage Typing , 2004, Journal of Clinical Microbiology.

[3]  A. Betts,et al.  Silk route to the acceptance and re-implementation of bacteriophage therapy. , 2016, Biotechnology journal.

[4]  Takashi Yamada,et al.  Loss of virulence of the phytopathogen Ralstonia solanacearum through infection by φRSM filamentous phages. , 2012, Phytopathology.

[5]  Mikael Skurnik,et al.  Phage therapy: facts and fiction. , 2006, International journal of medical microbiology : IJMM.

[6]  A. Buckling,et al.  Quality and Safety Requirements for Sustainable Phage Therapy Products , 2015, Pharmaceutical Research.

[7]  C. Rees,et al.  Bacteriophage applications: where are we now? , 2010, Letters in applied microbiology.

[8]  Jairam Ramesh,et al.  Trade-offs , 2014, Current Biology.

[9]  D. Lindsay,et al.  Isolation of Dermatophilus congolensis phage from the ‘Lumpy Wool’ of sheep in Western Australia , 1995, Letters in applied microbiology.

[10]  Rustam I. Aminov,et al.  A Brief History of the Antibiotic Era: Lessons Learned and Challenges for the Future , 2010, Front. Microbio..

[11]  O. Dereure,et al.  Human Skin Microbiota: High Diversity of DNA Viruses Identified on the Human Skin by High Throughput Sequencing , 2012, PloS one.

[12]  B. Martínez,et al.  Bacteriophages and their application in food safety , 2008, Letters in applied microbiology.

[13]  Aidan Coffey,et al.  Bacteriophages and Bacterial Plant Diseases , 2017, Front. Microbiol..

[14]  C. Rm.  Phage therapy: past history and future prospects. , 1999 .

[15]  I. Huys,et al.  Call for a Dedicated European Legal Framework for Bacteriophage Therapy , 2014, Archivum Immunologiae et Therapiae Experimentalis.

[16]  Q. Shen,et al.  Parasites and competitors suppress bacterial pathogen synergistically due to evolutionary trade‐offs , 2016, Evolution; international journal of organic evolution.

[17]  A. Buckling,et al.  Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms , 2012, Evolutionary applications.

[18]  K. A. Miroshnikov,et al.  Molecular architecture of bacteriophage T4 , 2004, Biochemistry (Moscow).

[19]  Mark A Mueller,et al.  Phage therapy reduces Campylobacter jejuni colonization in broilers. , 2005, Veterinary microbiology.

[20]  K. Servick.  DRUG DEVELOPMENT. Beleaguered phage therapy trial presses on. , 2016, Science.

[21]  K. V. Van Vliet,et al.  Genetically Engineered Phage Fibers and Coatings for Antibacterial Applications , 2010 .

[22]  U. Qimron,et al.  Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria , 2015, Proceedings of the National Academy of Sciences.

[23]  R. Murray.  Taxonomic Note: A Rule about the Deposition of Type Strains , 1996 .

[24]  Dominic Sauvageau,et al.  Host receptors for bacteriophage adsorption. , 2016, FEMS microbiology letters.

[25]  Y. Que,et al.  Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence , 2016, The Journal of infectious diseases.

[26]  S. Abedon,et al.  Phage therapy in clinical practice: treatment of human infections. , 2010, Current pharmaceutical biotechnology.

[27]  V. Jansen,et al.  Pharmacokinetic Principles of Bacteriophage Therapy , 2003, Clinical pharmacokinetics.

[28]  N. Chanishvili,et al.  Bacteriophage therapy: experience from the Eliava Institute, Georgia , 2008 .

[29]  H. Ackermann,et al.  Biological inactivation of adhering Listeria monocytogenes by listeriaphages and a quaternary ammonium compound , 1993, Applied and environmental microbiology.

[30]  Roberto Bastías,et al.  Virulence reduction in bacteriophage resistant bacteria , 2015, Front. Microbiol..

[31]  A. Fauconnier.  Regulating phage therapy , 2017, EMBO reports.

[32]  R. P. Ross,et al.  Phage therapy in the food industry. , 2014, Annual review of food science and technology.